Gillett C - Search Results

1

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. Turner N, et al. Among authors: gillett c. Cancer Res. 2010 Mar 1;70(5):2085-94. doi: 10.1158/0008-5472.CAN-09-3746. Epub 2010 Feb 23. Cancer Res. 2010. PMID: 20179196 Free PMC article.

2

Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.

Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G. Dickson C, et al. Among authors: gillett c. Cancer Lett. 1995 Mar 23;90(1):43-50. doi: 10.1016/0304-3835(94)03676-a. Cancer Lett. 1995. PMID: 7720042 Review.

3

Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Gillett C, et al. Cancer Res. 1994 Apr 1;54(7):1812-7. Cancer Res. 1994. PMID: 8137296

4

Cyclin D1 and prognosis in human breast cancer.

Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. Gillett C, et al. Int J Cancer. 1996 Apr 22;69(2):92-9. doi: 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q. Int J Cancer. 1996. PMID: 8608989

5

Cyclin D1 in breast cancer.

Barnes DM, Gillett CE. Barnes DM, et al. Among authors: gillett ce. Breast Cancer Res Treat. 1998;52(1-3):1-15. doi: 10.1023/a:1006103831990. Breast Cancer Res Treat. 1998. PMID: 10066068 Review.

6

Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor.

Cooper LS, Gillett CE, Patel NK, Barnes DM, Fentiman IS. Cooper LS, et al. Among authors: gillett ce. Cancer. 1999 Nov 15;86(10):2053-8. doi: 10.1002/(sici)1097-0142(19991115)86:10<2053::aid-cncr24>3.0.co;2-h. Cancer. 1999. PMID: 10570431

7

A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells.

Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J, Desprez PY. Lin CQ, et al. Among authors: gillett ce. Cancer Res. 2000 Mar 1;60(5):1332-40. Cancer Res. 2000. PMID: 10728695

8

Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.

Srinivasan R, Gillett CE, Barnes DM, Gullick WJ. Srinivasan R, et al. Among authors: gillett ce. Cancer Res. 2000 Mar 15;60(6):1483-7. Cancer Res. 2000. PMID: 10749108

9

MSI-low, a real phenomenon which varies in frequency among cancer types.

Halford SE, Sawyer EJ, Lambros MB, Gorman P, Macdonald ND, Talbot IC, Foulkes WD, Gillett CE, Barnes DM, Akslen LA, Lee K, Jacobs IJ, Hanby AM, Ganesan TS, Salvesen HB, Bodmer WF, Tomlinson IP, Roylance RR. Halford SE, et al. Among authors: gillett ce. J Pathol. 2003 Nov;201(3):389-94. doi: 10.1002/path.1453. J Pathol. 2003. PMID: 14595750

10

A role for endothelin-2 and its receptors in breast tumor cell invasion.

Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. Grimshaw MJ, et al. Among authors: gillett ce. Cancer Res. 2004 Apr 1;64(7):2461-8. doi: 10.1158/0008-5472.can-03-1069. Cancer Res. 2004. PMID: 15059899

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

201 results

Search Page